title: Response to Eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations.
authors.affiliation: Division of Critical Care Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA drarunsaini@gmail.com.
authors.forename: Arun
authors.initials: A
authors.lastname: Saini
authors.affiliation: Division of Critical Care Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: Amanda R
authors.initials: AR
authors.lastname: Emke
authors.affiliation: Division of Critical Care Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: Manuel C
authors.initials: MC
authors.lastname: Silva
authors.affiliation: Division of Neurology and Behavioural Pediatrics, Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
authors.forename: Seth J
authors.initials: SJ
authors.lastname: Perlman
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002675:Child, Preschool; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy*; D019453:Escherichia coli O157 / Q000187:drug effects*; D017809:Fatal Outcome; D006463:Hemolytic-Uremic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D008297:Male; D013226:Status Epilepticus / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab